Armata Pharmaceuticals (NYSE: ARMP) is one of 163 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Armata Pharmaceuticals to related companies based on the strength of its dividends, earnings, institutional ownership, profitability, risk, analyst recommendations and valuation.
Valuation & Earnings
This table compares Armata Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Armata Pharmaceuticals||$120,000.00||-$19.48 million||-1.24|
|Armata Pharmaceuticals Competitors||$661.51 million||$117.32 million||-5.13|
This is a summary of recent ratings and price targets for Armata Pharmaceuticals and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Armata Pharmaceuticals Competitors||1515||4555||9064||409||2.54|
As a group, “Biological products, except diagnostic” companies have a potential upside of 28.46%. Given Armata Pharmaceuticals’ peers higher probable upside, analysts plainly believe Armata Pharmaceuticals has less favorable growth aspects than its peers.
Risk and Volatility
Armata Pharmaceuticals has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500. Comparatively, Armata Pharmaceuticals’ peers have a beta of 1.28, meaning that their average share price is 28% more volatile than the S&P 500.
This table compares Armata Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Armata Pharmaceuticals Competitors||-3,865.74%||-95.75%||-41.46%|
Institutional and Insider Ownership
4.6% of Armata Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.8% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 22.2% of Armata Pharmaceuticals shares are owned by insiders. Comparatively, 17.8% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Armata Pharmaceuticals Company Profile
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating diseases caused by pseudomonas aeruginosa. The company is headquartered in Marina del Rey, California.
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.